William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sami Corwin has given his Buy rating due to a combination of factors influencing Krystal Biotech’s potential for growth. The company has shown promising signs with its product Vyjuvek, despite a slight dip in U.S. revenues. The updated U.S. label and an expanded salesforce are expected to drive future growth, while the ex-U.S. launches are anticipated to be significant contributors to revenue in the near term.
Additionally, the company’s clinical pipeline, particularly in cystic fibrosis and ophthalmology, is seen as a catalyst for future growth. The potential of KB801 to become a major revenue driver, if it achieves favorable outcomes, adds to the positive outlook. Corwin believes that the current valuation of the company does not fully reflect its long-term revenue potential, leading to a positive forecast for 2025 revenue and net income.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $240.00 price target.